{"title":"仍在寻找失踪的家族性高胆固醇血症患者","authors":"D. Ansell","doi":"10.15761/jccr.1000101","DOIUrl":null,"url":null,"abstract":"Received: September 04, 2018; Accepted: September 19, 2018; Published: September 24, 2018 In 2013 the European Atherosclerosis panel [1] highlighted the under diagnosis and under treatment of patients with heterozygous familial hypercholesterolaemia (heFH) in most, if not all, European countries. In the UK, NICE recently updated its clinical guideline (CG71) to primary care doctors for screening patients and identifying patients with heFH [2]. Are we any closer to knowing the true prevalence of heFH?","PeriodicalId":22442,"journal":{"name":"The Cardiology","volume":"2 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2018-09-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Still seeking the missing patients with familial hypercholesterolemia\",\"authors\":\"D. Ansell\",\"doi\":\"10.15761/jccr.1000101\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Received: September 04, 2018; Accepted: September 19, 2018; Published: September 24, 2018 In 2013 the European Atherosclerosis panel [1] highlighted the under diagnosis and under treatment of patients with heterozygous familial hypercholesterolaemia (heFH) in most, if not all, European countries. In the UK, NICE recently updated its clinical guideline (CG71) to primary care doctors for screening patients and identifying patients with heFH [2]. Are we any closer to knowing the true prevalence of heFH?\",\"PeriodicalId\":22442,\"journal\":{\"name\":\"The Cardiology\",\"volume\":\"2 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2018-09-19\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"The Cardiology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.15761/jccr.1000101\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"The Cardiology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.15761/jccr.1000101","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Still seeking the missing patients with familial hypercholesterolemia
Received: September 04, 2018; Accepted: September 19, 2018; Published: September 24, 2018 In 2013 the European Atherosclerosis panel [1] highlighted the under diagnosis and under treatment of patients with heterozygous familial hypercholesterolaemia (heFH) in most, if not all, European countries. In the UK, NICE recently updated its clinical guideline (CG71) to primary care doctors for screening patients and identifying patients with heFH [2]. Are we any closer to knowing the true prevalence of heFH?
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
